title: Use of sorafenib for post-transplant relapse in FLT3/ITD-positive acute myelogenous leukemia: maturation induction and cytotoxic effect.
authors.affiliation: Division of Hematology-Oncology and Transplantation, Department of Medicineand, Minneapolis, MN, USA.
authors.forename: Jessica
authors.initials: J
authors.lastname: Liegel
authors.affiliation: Department of Pathology and Laboratory Medicine University of Minnesota, Minneapolis, MN, USA.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Courville
authors.affiliation: Division of Hematology-Oncology and Transplantation, Department of Medicineand, Minneapolis, MN, USA.
authors.forename: Zohar
authors.initials: Z
authors.lastname: Sachs
authors.affiliation: Division of Hematology-Oncology and Transplantation, Department of Medicineand, Minneapolis, MN, USA custun@umn.edu.
authors.forename: Celalettin
authors.initials: C
authors.lastname: Ustun
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D005260:Female; D020440:Gene Duplication; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D012008:Recurrence; D019233:Retreatment; D000077157:Sorafenib; D020080:Tandem Repeat Sequences; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib; D051941:fms-Like Tyrosine Kinase 3
keywords: myeloid maturation; sorafenib; tyrosine kinase inhibitors